Details for Patent: 8,084,483
Which drugs does patent 8,084,483 protect, and when does it expire?
Patent 8,084,483 protects DUZALLO and ZURAMPIC and is included in two NDAs.
This patent has ninety-two patent family members in thirty-seven countries.
Summary for Patent: 8,084,483
| Title: | Compounds and compositions and methods of use | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Barry D. Quart, Jean-Luc Girardet, Esmir Gunic, Li-Tain Yeh | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Ardea Biociences Inc | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US12/324,764 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Drug Patent 8,084,483: Scope, Claims, Exclusivity, and Lesinurad Patent LandscapeUS Patent No. 8,084,483 protects methods of lowering serum uric acid with a defined class of heterocyclic compounds, including lesinurad and its pharmaceutically acceptable salts. The claims cover the active pharmaceutical ingredient, oral administration, tablets and capsules, selected excipients, gout treatment, and combination therapy with xanthine oxidase or other urate-lowering agents. The patent is associated with Ardea Biosciences’ lesinurad program and the FDA-approved product Zurampic. The patent’s strongest commercial coverage is directed to administering lesinurad, particularly the sodium salt, for hyperuricemia and gout. The formulation claims are narrower and require the claimed active compound to be administered in a composition containing specified dosage-form or excipient characteristics. What drug does US Patent 8,084,483 protect?US 8,084,483 primarily protects lesinurad-based uric-acid-lowering therapy. Lesinurad is a selective uric acid transporter 1, or URAT1, inhibitor. Its chemical structure corresponds to the preferred species covered by the patent’s formula IV and by the narrower claim combinations requiring:
The marketed drug was lesinurad, supplied as the sodium salt in 200-mg tablets under the brand name Zurampic. FDA approved Zurampic in December 2015 for use with a xanthine oxidase inhibitor in adults with gout-associated hyperuricemia when the target serum uric acid level was not achieved with a xanthine oxidase inhibitor alone.[1] The patent is therefore important because its claims reach both the underlying active compound and the clinical use that supported Zurampic’s approval. What are the independent claims in US 8,084,483?The two principal independent claims are claims 1 and 26. Claim 1: Markush method claimClaim 1 covers a method of reducing serum uric acid in a human by administering a compound of formula III, or a pharmaceutically acceptable salt, ester, or tautomer. The claim requires:
Claim 1 is a method-of-treatment claim, not a pure composition-of-matter claim. Infringement requires practice of the claimed therapeutic method, generally through administration to a human. A product sale can create indirect or induced-infringement exposure where labeling, promotional materials, or other conduct encourage the claimed use. The Markush structure gives claim 1 breadth across specified substituent positions. Its practical commercial value is narrower than its literal chemical breadth because the claim still requires the full formula III framework and the defined substituents. Claim 26: Formula IV species claimClaim 26 independently covers a method of reducing serum uric acid by administering a compound of formula IV, or a pharmaceutically acceptable salt, ester, or tautomer. Formula IV is the more commercially significant species claim because it identifies the preferred lesinurad structure rather than relying only on the broader formula III genus. A generic product containing lesinurad sodium and labeled for urate-lowering treatment would present a direct claim-mapping issue under claim 26, subject to the patent’s enforceability and remaining term. How do the dependent claims narrow the patent scope?The dependent claims divide the patent into chemical, pharmaceutical, dosage-form, disease, and combination-treatment limitations. Chemical limitationsClaims 2 through 7 narrow formula III as follows:
Claim 6 is particularly important because it converges toward the lesinurad species while remaining dependent on claim 1. Claim 7 separately identifies formula IV and can provide a cleaner species-level infringement theory than the broader Markush claim. Salt and pharmaceutical-form limitationsClaims 8 and 9 cover salt forms. Claim 8 lists ammonium, primary amine, secondary amine, tertiary amine, lithium, sodium, potassium, calcium, magnesium, and aluminum salts. Claim 9 narrows that group to the sodium salt. The sodium-salt limitation directly corresponds to the active ingredient used in Zurampic. A product containing a different pharmaceutically acceptable salt could avoid claim 9 while remaining potentially exposed to claims 1, 7, or 26 if the broader claim language covers that salt. Claims 10 through 20 address pharmaceutical administration and dosage-form characteristics:
These claims are narrower than the active-compound claims. They are directed to a method of administering the active ingredient in a particular formulation, rather than to the tablet as an article standing alone. What gout and combination therapies are protected?Claims 21 through 25 address gout treatment and combination therapy. Claim 21 limits the patient population to humans with gout. Claim 22 requires administration of a second gout-treatment agent. Claim 23 identifies the second agent as a:
Claim 24 identifies allopurinol, febuxostat, FYX-051, or combinations. Claim 25 narrows the second agent to allopurinol. The combination claims are commercially relevant because the FDA-approved Zurampic label required use with a xanthine oxidase inhibitor. A lesinurad product marketed with instructions to use allopurinol could implicate claims 22 through 25, in addition to claims 1, 7, or 26. The claims do not require that the second agent be administered in the same tablet. Separate administration can satisfy a combination-treatment claim if the method requires administration of both agents to the same patient. What patent claims cover lesinurad sodium?The most relevant claims for lesinurad sodium are claims 9, 24, 25, and 26, together with the broader claims from which they depend.
The patent does not protect every possible formulation of lesinurad with equal force. A product may fall within the active-ingredient claims even if it avoids the narrower excipient claims. Conversely, a formulation claim requires the relevant administration method and the specified formulation element. When does US 8,084,483 lose exclusivity?The patent was granted on December 27, 2011. Its term is governed by the 20-year patent term measured from the earliest effective nonprovisional or international filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments.[2] Public patent-family records identify the application as part of the Ardea lesinurad patent family, with priority dating to 2007 and a US filing in 2008.[3] On that basis, the ordinary expiration is expected in 2028, subject to the official USPTO patent-term calculation and any adjustment recorded in the patent file. FDA regulatory exclusivity is separate from patent exclusivity. Zurampic’s New Chemical Entity exclusivity expired four years after FDA approval, in December 2019. That regulatory period did not determine the patent expiration date.[1] Exclusivity timeline
A patent expiration date should be confirmed against the USPTO Patent Center record, including the patent-term-adjustment calculation and any terminal disclaimer. The FDA Orange Book expiration entry is the operative reference for listed drug-patent information.[4] What is the Orange Book status of US 8,084,483?US 8,084,483 was listed in connection with Zurampic, NDA 207988. The listing covered the patent’s method-of-use protection for lesinurad-based treatment of hyperuricemia associated with gout. The Orange Book distinguishes between listed patents and FDA approval status. A product can be discontinued commercially while its patent remains unexpired. Likewise, the absence of current commercial sales does not itself eliminate a listed patent or prevent a future abbreviated new drug application, subject to the Orange Book listing and applicable patent certifications. For a generic applicant, the relevant certification would depend on whether the patent remains listed for the reference product and whether the proposed labeling includes the patented method. A Paragraph IV certification would assert that the listed patent is invalid, unenforceable, or not infringed. A Paragraph III certification would defer approval until patent expiration. Which companies challenged the lesinurad patent?The principal commercial sponsor was Ardea Biosciences, later acquired by AstraZeneca. AstraZeneca held the US rights associated with Zurampic after the acquisition and marketed the product in the United States. No major, publicly established Paragraph IV litigation campaign against US 8,084,483 is identified in the core public patent and FDA records associated with Zurampic. That does not eliminate the possibility of an ANDA certification or confidential pre-litigation activity. A definitive litigation position requires review of FDA Paragraph IV notifications, district-court dockets, and current Orange Book records. The absence of prominent reported litigation means the patent’s competitive risk has been driven more by patent expiration, product discontinuation, and commercial viability than by a publicly documented validity trial. How strong is the patent estate for lesinurad?The estate is strongest at the active-ingredient and therapeutic-use level and weaker at the excipient level. Stronger protectionThe following features create the principal enforcement value:
These claims can reach a conventional generic lesinurad product if the ANDA labeling includes the relevant treatment indication. Narrower protectionThe formulation claims are more vulnerable to design-around because they require specific excipients or dosage-form features. A generic developer could potentially formulate the product without one or more listed excipients, although it would still need to assess claims 1, 7, 9, 10, 21, 22, and 26. The combination claims also depend on the proposed labeling and actual use. A product labeled only for a non-gout indication, or with instructions that omit the claimed combination, could present a different infringement analysis. FDA labeling constraints limit the practical ability to omit a patented indication where the reference product’s approved use is central to the product’s regulatory pathway. What generic-entry risks exist?Generic entry would face three principal issues. Patent certification riskAn ANDA applicant would need to address listed Zurampic patents through Paragraph I, II, III, or IV certifications. A Paragraph IV certification could trigger litigation and a 30-month stay under the Hatch-Waxman framework if the NDA holder or patent owner filed suit within the statutory period.[5] Method-of-use labelingBecause US 8,084,483 is substantially a method patent, the scope of the proposed label matters. A skinny-label strategy could omit a patented indication where FDA regulations permit it. That strategy is more difficult where the patented use is central to the reference product’s approved labeling or where the remaining label would still encourage the patented use. Manufacturing and analytical barriersLesinurad is a small molecule, not a biologic. Biosimilar approval is therefore not relevant. A generic manufacturer would generally rely on ANDA bioequivalence rather than the biologics-license pathway. Manufacturing barriers are primarily chemical-process, impurity-control, polymorph, salt-selection, and formulation-development issues. US 8,084,483, based on the supplied claims, does not principally claim a manufacturing process. A separate process or solid-state patent could still create additional risk, but it cannot be inferred from this patent alone. Does US 8,084,483 protect the formulation or the active ingredient?It protects both, but through different claim types. Claims 1, 7, and 26 protect administration of the defined chemical compound. Claims 8 and 9 address salt forms. Claims 11 through 20 add pharmaceutical composition and dosage-form limitations. The patent does not operate as a broad, standalone product claim to every tablet containing lesinurad. Its formulation protection is method-based. The accused conduct must include administering the relevant formulation to a human, and the formulation must satisfy the specified claim limitations. How does this patent compare with other lesinurad protection?US 8,084,483 is best characterized as a core therapeutic-use patent in the lesinurad estate.
Other lesinurad patents may cover compounds, pharmaceutical compositions, dosing regimens, combination therapy, crystalline forms, or manufacturing processes. They must be analyzed separately by patent number and claim set. US 8,084,483 alone does not establish the full patent estate. What is the commercial exposure associated with the patent?Zurampic was approved as an add-on therapy for patients whose uric acid remained inadequately controlled with a xanthine oxidase inhibitor. That positioning limited the addressable market compared with allopurinol and febuxostat monotherapy. The product also carried significant renal-safety warnings and was later discontinued in the United States. As a result, the present commercial value of US 8,084,483 is likely lower than its original value at launch. Any residual value depends on:
Key Takeaways
FAQs About US Patent 8,084,483 and LesinuradIs US 8,084,483 a composition-of-matter patent?No. Based on the supplied claims, it is principally a method-of-treatment patent. It protects administering defined compounds, including lesinurad, to reduce serum uric acid. Does US 8,084,483 cover Zurampic tablets?It can cover administration of Zurampic tablets where the tablet contains the claimed lesinurad form and satisfies the relevant method and formulation limitations. Claim 9 is particularly relevant to the sodium salt. Can a generic avoid US 8,084,483 by using a different excipient?Avoiding a listed excipient may avoid a narrow formulation claim, but it would not necessarily avoid the broader active-compound or treatment claims. Is a Paragraph IV challenge required for a generic lesinurad product?It may be required if the patent remains listed and unexpired and the applicant seeks approval before the listed patent expiration. The certification depends on the Orange Book listing and the proposed ANDA labeling. Does US 8,084,483 cover lesinurad with febuxostat?Claim 24 expressly identifies febuxostat as a possible second agent, subject to all other limitations of the claim. Claim 23 also covers broader categories of urate-lowering inhibitors. References
More… ↓ |
Drugs Protected by US Patent 8,084,483
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironwood Pharms Inc | DUZALLO | allopurinol; lesinurad | TABLET;ORAL | 209203-001 | Aug 18, 2017 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE | ⤷ Start Trial | ||||
| Ironwood Pharms Inc | DUZALLO | allopurinol; lesinurad | TABLET;ORAL | 209203-002 | Aug 18, 2017 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE | ⤷ Start Trial | ||||
| Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | REDUCTION OF SERUM URIC ACID LEVELS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,084,483
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2217577 | ⤷ Start Trial | 2016016 | Norway | ⤷ Start Trial |
| European Patent Office | 2217577 | ⤷ Start Trial | CA 2019 00003 | Denmark | ⤷ Start Trial |
| European Patent Office | 2217577 | ⤷ Start Trial | PA2019003 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2217577 | ⤷ Start Trial | 300970 | Netherlands | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
